Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Leslie SW, Siref LE. Cancer, Prostate. Treasure Island (FL): StatPearls; 2018.
   Google Scholar
• Ge JJ, Wang LT, Chen P, et al. Two new tetracyclic triterpenoids from the barks of Melia azedarach. J Asian Nat Prod Res. 2016;18:20–25.
   PubMed Web of Science ®Google Scholar
• Hasima N, Ozpolat B. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis. 2014;5:e1509.
   PubMed Web of Science ®Google Scholar
• Maioli E, Torricelli C, Valacchi G. Rottlerin and cancer: novel evidence and mechanisms. ScientificWorldJournal. 2012;2012:350826.
   PubMedGoogle Scholar
• Koo KH, Jeong WJ, Cho YH, et al. K-Ras stabilization by estrogen via PKCdelta is involved in endometrial tumorigenesis. Oncotarget. 2015;6:21328–21340.
   PubMedGoogle Scholar
• Song KS, Kim JS, Yun EJ, et al. Rottlerin induces autophagy and apoptotic cell death through a PKC-delta-independent pathway in HT1080 human fibrosarcoma cells: the protective role of autophagy in apoptosis. Autophagy. 2008;4:650–658.
   PubMed Web of Science ®Google Scholar
• Lim JH, Park JW, Choi KS, et al. Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells. Carcinogenesis. 2009;30:729–736.
   PubMed Web of Science ®Google Scholar
• Lim JH, Park JW, Kim SH, et al. Rottlerin induces pro-apoptotic endoplasmic reticulum stress through the protein kinase C-delta-independent pathway in human colon cancer cells. Apoptosis. 2008;13:1378–1385.
   PubMed Web of Science ®Google Scholar
• Maioli E, Daveri E, Maellaro E, et al. Non-conventional rottlerin anticancer properties. Arch Biochem Biophys. 2018;645:50–53.
   PubMed Web of Science ®Google Scholar
• Lu W, Lin C, Li Y. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/beta-catenin and mTORC1 signaling in prostate and breast cancer cells. Cell Signal. 2014;26:1303–1309.
   PubMed Web of Science ®Google Scholar
• Kumar D, Shankar S, Srivastava RK. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett. 2014;343:179–189.
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624–629.
   PubMed Web of Science ®Google Scholar
• Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22:128–134.
   PubMed Web of Science ®Google Scholar
• Gan L, Yang Y, Li Q, et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.
   PubMed Web of Science ®Google Scholar
• Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J. 2003;22:5323–5335.
   PubMed Web of Science ®Google Scholar
• Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24:268–273.
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7:299–313.
   PubMed Web of Science ®Google Scholar
• Yan KS, Lin CY, Liao TW, et al. EZH2 in cancer progression and potential application in cancer therapy: a friend or foe?. Int J Mol Sci. 2017;6.
   Web of Science ®Google Scholar
• Herrera-Merchan A, Arranz L, Ligos JM, et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun. 2012;3:623.
   PubMed Web of Science ®Google Scholar
• Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100:11606–11611.
   PubMed Web of Science ®Google Scholar
• Chien YC, Liu LC, Ye HY, et al. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res. 2018;8:422–434.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yang P, Li W, et al. Expression of EZH2 is associated with poor outcome in colorectal cancer. Oncol Lett. 2018;15:2953–2961.
   PubMed Web of Science ®Google Scholar
• Lee SR, Roh YG, Kim SK, et al. Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer. Clin Cancer Res. 2015;21:5391–5403.
   PubMed Web of Science ®Google Scholar
• Basu A, Adkins B, Basu C. Down-regulation of caspase-2 by rottlerin via protein kinase C-delta-independent pathway. Cancer Res. 2008;68:2795–2802.
   PubMed Web of Science ®Google Scholar
• Ohno I, Eibl G, Odinokova I, et al. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol. 2010;298:G63–G73.
   PubMed Web of Science ®Google Scholar
• Wang Z, Shen GH, Xie JM, et al. Rottlerin upregulates DDX3 expression in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018;495:1503–1509.
   PubMed Web of Science ®Google Scholar
• Huang M, Tang SN, Upadhyay G, et al. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice. Cancer Lett. 2014;353:32–40.
   PubMed Web of Science ®Google Scholar
• Lim JH, Woo SM, Min KJ, et al. Rottlerin induces apoptosis of HT29 colon carcinoma cells through NAG-1 upregulation via an ERK and p38 MAPK-dependent and PKC delta-independent mechanism. Chem Biol Interact. 2012;197:1–7.
   PubMed Web of Science ®Google Scholar
• Torricelli C, Daveri E, Salvadori S, et al. Phosphorylation-independent mTORC1 inhibition by the autophagy inducer Rottlerin. Cancer Lett. 2015;360:17–27.
   PubMed Web of Science ®Google Scholar
• Singh BN, Kumar D, Shankar S, et al. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. Biochem Pharmacol. 2012;84:1154–1163.
   PubMed Web of Science ®Google Scholar
• Kumar D, Shankar S, Srivastava RK. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms. Mol Cancer. 2013;12:171.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Lin CY, Chen Y, et al. Rottlerin inhibits migration of follicular thyroid carcinoma cells by PKCdelta-independent destabilization of the focal adhesion complex. J Cell Biochem. 2010;110:428–437.
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang Y, Su J, et al. Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells. Oncotarget. 2016;7:66512–66524.
   PubMedGoogle Scholar
• Su J, Wang L, Yin X, et al. Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells. Am J Cancer Res. 2016;6:2178–2191.
   PubMed Web of Science ®Google Scholar
• Wang L, Hou Y, Yin X, et al. Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells. Oncotarget. 2016;7:69770–69782.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zheng N, Wang L, et al. Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer. Oncotarget. 2017;8:7827–7838.
   PubMedGoogle Scholar
• Hou Y, Feng S, Wang L, et al. Inhibition of Notch-1 pathway is involved in rottlerin-induced tumor suppressive function in nasopharyngeal carcinoma cells. Oncotarget. 2017;8:62120–62130.
   PubMedGoogle Scholar
• Xu B, Konze KD, Jin J, et al. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol. 2015;43:698–712.
   PubMed Web of Science ®Google Scholar
• Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. 2008;32:491–502.
   PubMed Web of Science ®Google Scholar
• Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050–1063.
   PubMed Web of Science ®Google Scholar
• Song X, Zhang L, Gao T, et al. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation. Biomed Pharmacother. 2016;81:288–294.
   PubMed Web of Science ®Google Scholar
• Verma SK, Tian X, LaFrance LV, et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett. 2012;3:1091–1096.
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108–112.
   PubMed Web of Science ®Google Scholar
• Konze KD, Ma A, Li F, et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8:1324–1334.
   PubMed Web of Science ®Google Scholar
• Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110:7922–7927.
   PubMed Web of Science ®Google Scholar
• Ide H, Lu Y, Noguchi T, et al. Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. Cancer Sci. 2018;109:1230–1238.
   PubMed Web of Science ®Google Scholar
• Wang R, Li Y, Hou Y, et al. The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget. 2015;6:7000–7010.
   PubMedGoogle Scholar
• Li X, Yokoyama NN, Zhang S, et al. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget. 2015;6:41809–41824.
   PubMedGoogle Scholar
• Huang MH, Lin SZ, Lin PC, et al. Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability. Tumour Biol. 2014;35:4875–4884.
   PubMedGoogle Scholar